Clinical trials: Vascular Disease
Moderate to Severe Hypertension
Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension
This study will compare the blood pressure (BP) lowering effect of the combination of aliskiren/amlodipine 300/10 mg versus amlodipine 10 mg monotherapy in patients with moderate to severe hypertension by testing the hypothesis…
- Trial name
- NCT00841672
- Testing
- Aliskiren/amlodipine 300/10 mg tablet, Amlodipine 10 mg capsule
- Where
- 6 sites in Germany, Philippines and 4 more
- Volunteers
- 485 people
- Sponsor
- Novartis
Venous Thrombosis, Pulmonary Embolism
BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery
The purpose of this study is to learn if BMS-562247 can prevent blood clots in the legs and lungs in men and women following unilateral total knee replacement surgery. The safety of this treatment will also be studied.
- Trial name
- NCT00097357
- Testing
- Apixaban, Enoxaparin, Warfarin
- Where
- 147 sites in United States, Argentina and 7 more
- Volunteers
- 1,238 people
- Sponsor
- Bristol-Myers Squibb
Diabetes Mellitus, Type 2, Hypertension
Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities
This study is to assess the safety and performance of the Neurotronic Infusion Catheter and ethanol denervation of renal and hepatic arteries for the treatment of patients with Type 2 Diabetes (T2DM), Hypertension and Obesity.
- Trial name
- NECTAR IV (NCT05369065)
- Testing
- Ablation Treatment, Arterial Angiography Only, Single Arm non-Randomized Ablation Treatment
- Where
- 3 sites in Georgia
- Volunteers
- 60 people
- Sponsor
- Neurotronic, Inc.
Atherosclerosis
Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).
Darapladib (SB-480848) is a novel, selective, orally active inhibitor of lipoprotein associated phospholipase A2 (Lp-PLA2) currently under clinical development by GlaxoSmithKline as a potential anti-atherosclerosis agent for…
- Trial name
- NCT01852565
- Testing
- Darapladib, Diltiazem
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
End Stage Renal Disease, AV Fistula
Percutaneous Less Invasive AV Fistula for Vascular Access in ESRD
A prospective single-arm well-controlled study to evaluate the safety and effectiveness of a less invasive means of establishing vascular access to facilitate dialysis in patients with end stage renal disease.
- Conditions
- End Stage Renal Disease, AV Fistula, Fistula, End Stage Kidney Disease
- Trial name
- NCT02363972
- Testing
- Ellipsys Vascular Access Catheter
- Where
- 5 sites in United States
- Volunteers
- 103 people
- Sponsor
- Medtronic Endovascular
Multiple Myeloma
A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients
The primary reason for this study is to further assess safety and efficacy data of the bortezomib/melphalan/prednisone (BMP) regimen in previously untreated and transplant ineligible multiple myeloma patients
- Trial name
- NCT00799539
- Testing
- bortezomib, melphalan, prednisone
- Where
- 3 sites in Canada
- Sponsor
- Janssen-Ortho Inc., Canada
Aneurysms
A Study to Look at Performance of MICRUSFRAME and GALAXY Coils for the Treatment of Intracranial Aneurysms
A post-market registry evaluating ruptured/unruptured aneurysms treated with MICRUSFRAME and GALAXY coils
- Trial name
- STERLING (NCT03642639)
- Testing
- MICRUSFRAME and GALAXY coils
- Where
- 51 sites in United States, Belgium and 8 more
- Volunteers
- 723 people
- Sponsor
- Cerenovus, Part of DePuy Synthes Products, Inc.
Plasma Cell Myeloma
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Primary Objective: -To demonstrate the benefit of isatuximab in combination with bortezomib, lenalidomide, and dexamethasone in the prolongation of progression free survival (PFS) as compared to bortezomib, lenalidomide, and…
- Trial name
- IMROZ (NCT03319667)
- Testing
- Isatuximab SAR650984, Bortezomib, Lenalidomide
- Where
- 104 sites in United States, Australia and 19 more
- Volunteers
- 475 people
- Sponsor
- Sanofi
Intracranial Atherosclerosis
A Study of Implantation of CRENEOUS ENTERPRISE 2 Intracranial Stent in Participants With Severe Symptomatic Intracranial Atherosclerotic Stenosis
The purpose of this study is to evaluate the safety and effectiveness of CERENOVUS ENTERPRISE 2 intracranial stent implantation in treatment of participants with severe symptomatic intracranial atherosclerotic stenosis.
- Trial name
- NCT05316311
- Testing
- CERENOVUS ENTERPRISE 2 Intracranial Stent
- Where
- 14 sites in China
- Volunteers
- 194 people
- Sponsor
- Medos International SARL
Hypertension, Atrial Fibrillation
A Cross-sectional Study for the Determination of the Prevalence of Non-valvular Atrial Fibrillation Among Patients Diagnosed With Hypertension
Arterial hypertension has been recognized as a major causal factor for atrial fibrillation (AF), the most common sustained cardiac arrhythmia.
- Trial name
- REFINE HT (NCT02585076)
- Testing
- Standard of care
- Where
- Greece
- Volunteers
- 1,119 people
- Sponsor
- Bayer
Refractory, Multiple Myeloma
A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients
The purpose of this study is to assess the safety/tolerability and determine the Japanese recommended dose (RD) of bortezomib administered as a once-daily intravenous bolus twice weekly for 2 consecutive weeks(Days 1, 4, 8, and…
- Conditions
- Refractory, Multiple Myeloma, Relapse
- Trial name
- NCT00752518
- Testing
- bortezomib
- Volunteers
- 35 people
- Sponsor
- Janssen Pharmaceutical K.K.
Open-Angle Glaucoma, Ocular Hypertension
A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to demonstrate equivalent safety and IOP-lowering effectiveness of two Travoprost/Timolol combination products in patients diagnosed with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00672997
- Testing
- Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution, Travoprost 0.004%/Timolol 0.5% ophthalmic solution
- Volunteers
- 301 people
- Sponsor
- Alcon Research
Aortic Diseases
Percutaneous Endovascular Arch Repair Trial (PEART) Study
This study is the feasible study on a new technique of ZIPPER aortic arch stentgraft system
- Trial name
- NCT05872282
- Testing
- ZIPPER aortic arch stentgraft system
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Hangzhou Endonom Medtech Co., Ltd.
Treatment of Acute Coronary Syndrome (ACS).
REalWorld Insights on the INitiation and Treatment Duration of ticagrEloR & Other Oral Antiplatelets (OAP) in Patients With Acute Coronary Syndrome (ACS) in Be/Lux.
REWINDER is a multinational, multicentre, non-interventional, retrospective study of patients treated with an oral antiplatelet (ticagrelor, prasugrel or clopidogrel) while in hospital after an acute coronary syndrome (ACS)…
- Trial name
- REWINDER (NCT02190123)
- Testing
- ACS patients treated with OAP
- Where
- 15 sites in Belgium
- Volunteers
- 430 people
- Sponsor
- AstraZeneca
Myeloma Multiple
A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)
The aim of the study is to assess the efficacy and safety of the BCD-248 in combination with daratumumab versus the combination of daratumumab, pomalidomide, and dexamethasone in the treatment of relapsed or refractory multiple…
- Trial name
- AMMADINA (NCT07742215)
- Testing
- BCD-248 + daratumumab, Daratumumab + pomalidomide + dexamethasone
- Where
- 16 sites in Belarus, Russia
- Volunteers
- 390 people
- Sponsor
- Biocad
Peripheral Artery Disease, Atherosclerosis
Clinical Use and Safety of the Xtreme Touch (Magic Touch PTA)- Neo Sirolimus Coated PTA Balloon Catheter in the Treatment of Infrainguinal Peripheral Arterial Disease
This study postulates that the application of Sirolimus, an anti-proliferative agent that inhibits neointimal hyperplasia, via Sirolimus coated balloon (SCB) will be safe and will result in better arterial patency in…
- Trial name
- XTOSI (NCT04368091)
- Testing
- Xtreme Touch - Neo sirolimus coated PTA balloon catheter
- Where
- Singapore
- Volunteers
- 50 people
- Sponsor
- Concept Medical Inc.
Diabetes Mellitus, Coronary Artery Disease
Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)
This trial is designed as a phase 2 randomized, double-blind double dummy, active comparator controlled, two-period two-arm crossover study to enroll 40 patients across multiple centers.
- Trial name
- OPTIMUS-3 (NCT00642174)
- Testing
- prasugrel, Clopidogrel
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Relapsed/Refractory Multiple Myeloma
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011…
- Trial name
- CaMMouflage (NCT05722418)
- Testing
- CB-011
- Where
- 16 sites in United States
- Volunteers
- 50 people
- Sponsor
- Caribou Biosciences, Inc.
Hereditary Angioedema
CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks
This is a multicenter, double-blind, randomized, placebo-controlled, parallel-arm study to investigate the efficacy and safety of subcutaneous administration of CSL312 (garadacimab) in the prophylactic treatment of hereditary…
- Trial name
- NCT04656418
- Testing
- CSL312
- Where
- 28 sites in United States, Canada and 5 more
- Volunteers
- 64 people
- Sponsor
- CSL Behring
Acute Ischemic Stroke
Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke
This study is designed to determine the efficacy and safety of SHPL-49 intravenous infusion in acute ischemic stroke patients.
- Trial name
- SAIL (NCT07241520)
- Testing
- SHPL-49 Injection
- Where
- China
- Volunteers
- 1,096 people
- Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.